renal cell carcinoma

Clinigen buys remaining rights to Novartis cancer drug

https://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

Roche’s Tecentriq + Avastin racks up another combination success

https://pharmaphorum.com/news/tecentriq-avastin-combination-success/

NICE says no to Ipsen’s kidney cancer drug

https://pharmaphorum.com/news/nice-says-no-ipsens-kidney-cancer-drug/

NICE recommends Novartis kidney cancer drug

https://pharmaphorum.com/news/nice-backs-novartis-kidney-cancer-drug/

NICE does U-turn, backs Opdivo in kidney cancer

https://pharmaphorum.com/news/nice-u-turn-backs-opdivo-kidney-cancer/

Ipsen/Exelixis’ drug approved in EU for kidney cancer

https://pharmaphorum.com/news/ipsenexelixis-drug-approved-eu-kidney-cancer/

Close in 10 seconds

Pharmaphorum.com

Search